These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11863088)

  • 1. Modulation of 5-fluorouracil/leucovorin by trimetrexate--did it work?
    Bertino JR
    Ann Oncol; 2002 Jan; 13(1):10-1. PubMed ID: 11863088
    [No Abstract]   [Full Text] [Related]  

  • 2. Trimetrexate as a biochemical modulator of 5-fluorouracil and leucovorin in colorectal cancer.
    Punt CJ
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):88-90. PubMed ID: 11049038
    [No Abstract]   [Full Text] [Related]  

  • 3. Biomodulation of 5-fluorouracil with antifolates.
    Bertino JR
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimetrexate: review and current clinical experience in advanced colorectal cancer.
    Blanke CD; Messenger M; Taplin SC
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-57-S18-63. PubMed ID: 9420022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
    Blanke CD; Shultz J; Cox J; Modiano M; Isaacs R; Kasimis B; Schilsky R; Fleagle J; Moore M; Kemeny N; Carlin D; Hammershaimb L; Haller D
    Ann Oncol; 2002 Jan; 13(1):87-91. PubMed ID: 11863117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer.
    Punt CJ; Blanke CD; Zhang J; Hammershaimb L
    Ann Oncol; 2002 Jan; 13(1):92-4. PubMed ID: 11865815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study.
    Punt CJ; Keizer HJ; Douma J; Skovsgaard T; Schüller J; Muller EW; Ten Napel CH; Croles JJ; Lochs H; Zhang J; Hammershaimb L
    Ann Oncol; 2002 Jan; 13(1):81-6. PubMed ID: 11865814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction. Beyond 5-fluorouracil.
    Pazdur R
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):15-6. PubMed ID: 10442352
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose trimetrexate and minimal-dose leucovorin: a case for selective protection?
    Hum M; Holcenberg JS; Tkaczewski I; Weaver JW; Wilson J; Kamen BA
    Clin Cancer Res; 1998 Dec; 4(12):2981-4. PubMed ID: 9865909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomodulation of Fluorouracil in colorectal cancer.
    Ardalan B; Luis R; Jaime M; Franceschi D
    Cancer Invest; 1998; 16(4):237-51. PubMed ID: 9589033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successes in late solid tumors. New therapy offer].
    Arnheim K
    MMW Fortschr Med; 2004 Nov; 146(47):71. PubMed ID: 15624667
    [No Abstract]   [Full Text] [Related]  

  • 12. Selectivity in human breast cancer and human bone marrow using trimetrexate in combination with 5-fluorouracil.
    Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M
    Anticancer Res; 1999; 19(5B):3837-40. PubMed ID: 10628320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in advanced colorectal cancer.
    Conroy T; Guillemin F
    J Clin Oncol; 1999 May; 17(5):1644. PubMed ID: 10334556
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.
    Zaniboni A
    J Clin Oncol; 1997 Jun; 15(6):2432-41. PubMed ID: 9196159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant systemic chemotherapy with 5-fluorouracil and leucovorin in colon cancer: a monoinstitutional institutional experience.
    Jirillo A; Stefani M; Vascon F; Lonardi S
    Immunopharmacol Immunotoxicol; 2008; 30(2):235-42. PubMed ID: 18569081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Systemic palliative chemotherapy with 5-fluorouracil and leucovorin in disseminated colorectal cancer].
    Wiboltt K; Raskov HH
    Ugeskr Laeger; 1999 Jun; 161(25):3827-32. PubMed ID: 10412300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study.
    Punt CJ; Kamm YL; Wagener DJ
    Anticancer Drugs; 1997 Jun; 8(5):454-8. PubMed ID: 9215607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimetrexate: experience with solid tumors.
    Haller DG
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-71-S18-76. PubMed ID: 9420024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
    Scheithauer W; Kornek G; Marczell A; Salem G; Karner J; Kovats E; Burger D; Greiner R; Pidlich J; Schneeweiss B; Raderer M; Rosen H; Depisch D
    J Clin Oncol; 1997 Mar; 15(3):908-14. PubMed ID: 9060527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor.
    Cascino TL; Veeder MH; Buckner JC; O'Fallon JR; Wiesenfeld M; Levitt R; Goldberg RM; Kuross SA; Morton RF; Scheithauer BW
    J Neurooncol; 1996 Dec; 30(3):243-6. PubMed ID: 8943099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.